The Future of Laboratory-Developed Tests
Comments on the FDA’s proposed rule to regulate LDTs as in vitro diagnostic devices reveal mixed reactions.
Comments on the FDA’s proposed rule to regulate LDTs as in vitro diagnostic devices reveal mixed reactions.
On Oct. 28, the US Department of Health and Human Services served notice that it plans to repeal a controversial Trump rule.
From - Lab Compliance Advisor
While FDA oversight over new diagnostic tests is perfectly acceptable, what is objectionable is the…
From - G2 Compliance Advisor
After a series of court setbacks, Republicans challenging the constitutionality of Obamacare, aka, the Affordable Care Act (ACA) are back at it…
From - G2 Compliance Advisor
SITUATION
XYZ Consultants recommends that a hospital client cut costs by making 34 changes to its OR spinal fusion surgeries procedures…
From - G2 Compliance Advisor
SITUATION
Fictional Med (FM), a large physician-owned clinic, is one of your lab's biggest customers. So your heart sinks when…